PEB.NZX
Pacific Edge Limited
Our view
You need to become a client or login to see Forsyth Barr’s current view.
Recent research View all research
About Pacific Edge Limited
Pacific Edge is a cancer diagnostics company in the early stages of commercialisation of its first product, Cxbladder, after 10 years of research into genetic markers. Cxbladder is a suite of non-invasive urine tests to detect the presence of bladder cancer in patients presenting with haematuria. PEB has four Cxbladder products in the market: Detect, Triage, Monitor and Resolve. PEB also has a suite of products in various stages of development for melanoma, colorectal cancer, endometrial cancer and gastric cancer.
Forsyth Barr Analyst
-
Chelsea Leadbetter, Senior Analyst, Equities
[email protected]
DDI: +64 4 495 5262
Share price performance
All stock prices and news delayed 20 minutes
00:08 October 23rd 2018 NZDT
0.44 0.0%
0.43 Buy
0.44 Sell
Last 0.44
Open 0.44
High 0.44
Low 0.44
Volume 104,670
Turnover $45,531
Most recent trades All trades for the day
| Time | Price | Volume | Value |
|---|---|---|---|
| 16:39 | 0.44 | 444 | $193.14 |
| 16:39 | 0.44 | 35,000 | $15,225.00 |
| 16:39 | 0.44 | 1,556 | $676.86 |
| 16:35 | 0.44 | 10,000 | $4,350.00 |
| 14:41 | 0.44 | 444 | $193.14 |
Latest Pacific Edge Limited research
Today's trades
| Trade Number | Time | Price | Volume | Value |
|---|---|---|---|---|
| 8 | 16:39 | 0.44 | 444 | $193.14 |
| 7 | 16:39 | 0.44 | 35,000 | $15,225.00 |
| 6 | 16:39 | 0.44 | 1,556 | $676.86 |
| 5 | 16:35 | 0.44 | 10,000 | $4,350.00 |
| 4 | 14:41 | 0.44 | 444 | $193.14 |
| 3 | 14:41 | 0.44 | 671 | $291.89 |
| 2 | 13:41 | 0.44 | 1,000 | $435.00 |
| 1 | 11:09 | 0.44 | 4,128 | $1,795.68 |